Introduction
Noroviruses are a leading cause of food-or water-borne gastroenteritis outbreaks. Studies have demonstrated that noroviruses are responsible for more than 60% of all food-water-borne gastroenteritis outbreaks (Fankhauser et al., 1998) with an estimated 23 million cases annually in the US causing 50,000 hospitalizations and 300 deaths (Mead et al., 1999) . Studies of the replication of human noroviruses have been severely hampered by the absence of a cell culture system (Duizer et al., 2004) . To overcome this limitation, we have previously generated Norwalk virus (NV), the prototype strain of noroviruses, replicon-harboring cells in BHK21 and Huh-7 cells (Chang et al., 2006) . This replicon system has provided an excellent tool to study the replication of noroviruses and served as a platform to screen potential antiviral drugs (Chang, 2009; Chang and George, 2007b; Chang et al., 2006) . Using the NV replicon-harboring cells, we have previously demonstrated that the expression of replicon RNA and proteins was significantly reduced in the presence of various interferons (IFNs) including IFN-α and IFN-γ in a dose-dependent manner and suggested IFNs could be therapeutic options for norovirus infection (Chang, 2009; Chang and George, 2007b; Chang et al., 2006) . The important roles of IFN in replication and pathogenicity of noroviruses were also demonstrated using murine norovirus (MNV) in vitro (RAW267.4 cells) and in vivo (Changotra et al., 2009; Karst et al., 2003; Mumphrey et al., 2007) . Among the noroviruses, only MNVs including MNV-1 strain have been successfully propagated in cell culture (Wobus et al., 2004 ) and provides a cell culture model for norovirus research.
IFN therapy has been a part of standard treatment regime in some infectious viral diseases such as hepatitis B and C virus infection (Foster, 2010; Liu and Kao, 2006) , and its importance in respiratory viral infection including influenza virus has been studied extensively (Herzog et al., 1983; Isomura et al., 1982; Merigan et al., 1973; Phillpotts et al., 1983) . However, the short halflife of IFN (up to 8.5 hr) in the serum requires repeated administration to maintain effective concentration in targeted organs. To increase the half-life, IFN can be chemically conjugated with poly(ethylene glycol) (PEG) which is inert, water-soluble, and nontoxic and does not adversely affect the safety profile of the IFN (Foster, 2010; Kozlowski et al., 2001; Luxon et al., 2002; Sharieff et al., 2002; Shiffman, 2001) . The pegylated IFN significantly increases the stability of IFN and is used for treatment of hepatitis B and C virus infection commonly in combination with ribavirin (Aghemo et al., 2010; Foster, 2010; Husa and Husova, 2001; Liu and Kao, 2006) . The parental administration of high dose IFNs (international units [IU] in millions) is associated with side effects, one of the major causes of treatment failure (Negro, 2010) .
However, for virus infection occurring in mucosal areas, such as respiratory or gastroenteric infection, systemic administration of IFN may not be required. Therefore, oral or intranasal administration of IFNs has been explored as a way to reduce significant side effects and to introduce IFNs directly to the affected mucosal areas [review (Beilharz, 2010) ]. Nanogels are nanosized networks of chemically cross-linked polymers that swell in a solvent and provide improved stability and bioavailability to drugs (Vinogradov et al., 1999; Vinogradov et al., 2006) . We have synthesized nanogels based on cross-linked polyethyleneimine (PEI)-PEG, which were further acetylated to reduce cytotoxicity (AcNg). The IFN-AcNg complex was prepared by incubating two components together at 4°C in water and The preliminary study using rats suggested that IFN-AcNg did not cause side effects by oral or systemic administration, and AcNg did not cause IFN carryover to systemic circulation after oral administration of IFN-AcNg. We concluded that AcNg has a potential to be pursued as a vehicle for oral delivery of IFNs in norovirus infection. Recombinant IFN type I (human IFN-A+D fusion protein), mouse IFN-β, and human IFN-αA were purchased from Sigma-Aldrich (St Louis, MO). The polyclonal antibody specific to NV proteinase-polymerase (ProPol) was described in a previous report (Chang et al., 2006) . 2.2. Preparation of PEG/PEI nanogel. Nanogel PEG-PEI was prepared by following a method described previously (Ganta et al., 2008) . Briefly, 7.0 g of PEI (MW ~25 kDa) in 20 ml of deionized water was loaded into Sephacryl S200 chromatographic column. The middle fractions (based on weight distribution) were collected and lyophilized to give 3.64 g (0.146 mmol) of PEI (molecular weight [MW] ~25 kDa). To activate PEG, 2.0 g of PEG (MW 8 kDa) in 7 ml of dry acetonitrile under argon was added to 0.41 g (2.5 mmol) of 1,1′-carbonyldimidazole, and the solution was stirred at 40°C for 2 hrs. The crude product was purified by dialysis using a MW cut-off (MWCO) 2 kDa membrane with 10% ethanol in deionized water at 4°C for 4 hrs. The solution was lyophilized to give 1.84 g of activated PEG. Nanogel PEG-PEI was prepared by following a similar micellar method (Vinogradov et al., 2006) . Synthesis started from activated PEG (~63 μmol) and PEI (~40 μmol). The PEI in 300 ml of deionized water was added dropwise to a solution of activated PEG (MW ~8 kDa) in 2 ml of dichloromethane. The reaction solution was sonicated in a water bath for 10 min, and the organic solvent was removed on a rotary evaporator resulting in a transparent solution. The solution was dialyzed with a MWCO 12K -14K membrane in 800 ml of 10% ethanol in deionized water for 1 day at 25°C and lyophilized to give nanogel PEG-PEI (Ng). The qRT-PCR amplification was performed in a SmartCycler (Cepheid, Sunnyvale, CA) with the following parameters: 45°C for 30 min, and 95 °C 10 min, followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 50 °C for 1 min and elongation at 72°C for 30 s. For quantity control, qRT-PCR for -actin was performed as described previously (Spann et al., 2004) . The relative genome levels in cells with various treatments were calculated after the RNA levels were normalized with those of -actin. AcNg alone did not show any antiviral effects (not shown). 
The effects of IFN or AcNg-IFN treatment on ISRE-luc response in Vero and

Discussion
Norovirus infection continues to be an important cause of gastroenteritis in humans, the leading cause of foodborne disease followed by Salmonella contamination among laboratoryconfirmed single etiologic agent cases (CDC, 2010) . In most cases, norovirus infection leads to acute illness, even though recent findings demonstrated that the infection could last longer than several days or even several months, especially in immunocompromised patients (Nilsson et al., 2003) . Since noroviruses are very contagious and requires only a very low dose to cause an infection, it is classified as category B bioterrorism agents. However, there is no vaccine or treatments specific for norovirus infection except for supportive therapy including fluid administration to correct dehydration. Previously, we have used the recently developed NVreplicon harboring cells and demonstrated that IFN- and  were effective inhibitors of NV replication (Chang et al., 2006) . We also suggested that NV may not have strong means to counteract IFN systems, which further suggests the potential use of IFN in the control of noroviruses (Chang et al., 2006) . Other researchers have found that the replication of MNV-1 was sensitive to IFN system in vivo as well as in vitro (Changotra et al., 2009; Karst et al., 2003) . These results suggest that IFN could be potential therapeutic agent for norovirus infection.
IFN treatment in various virus infections including respiratory viruses or human hepatitis
viruses has been studied. Currently, the standard therapy for chronic HCV infection is the combination therapy of IFN- and ribavirin (Aghemo et al., 2010) . For treatment of HCV infection, IFNs chemically conjugated with branched or linear PEG (pegylated IFN) were recently licensed for longer half-life of IFN in parenteral administration (Jen et al., 2001) . PEG is inert, water-soluble, and nontoxic and does not adversely affect the safety profile of the IFN.
PEG exists in a multitude of molecular weights, and can be attached to IFN with size up to 40kD (Sharieff et al., 2002) . It was reported that higher molecular weight of PEG yields longer half-life of the conjugated IFN. However, due to physical conjugation to IFN, PEG reduces the bioactivity of IFN (Bailon et al., 2001; Monkarsh et al., 1997) . The parenteral administration of high dose of IFN (in HCV infection, the standard dose for IFN is above 1 million IU) could induce significant side effects such as influenza-like syndrome with fever, chills, myalgia, and malaise (Negro, 2010 ).
Due to these side effects associated with the high doses of parenteral administration of IFN, oral administration of IFN has been explored by many researchers for virus infection in mucosal surfaces [review (Beilharz, 2010) ]. In natural settings, humans and animals encounter various viruses and bacteria on daily basis and secret IFN in oral and nasal cavity (Beilharz, 2010) .
Interestingly, the oral administration of IFN was reported to be associated with no significant side effects (Dec and Puchalski, 2008) . In studies of oral administration of IFN in various animals, IFN was rarely detected in the blood, which may be related to the lack of side effects.
The oral IFN studies showed conflicting results on systemic effects of IFN. In humans, Witt et al (Witt et al., 1992) reported that oral administration of high dose of IFN (2.5 and 7.5 mg) to healthy volunteers did not significantly induce IFN-responding proteins in serum. However, interestingly, low oral dose of IFN (125 IU) were more effective than intramuscular dose of millions (IU) in inducing 2',5'-OAS activity in the blood (Uno et al., 2006) , and oromucosal delivery of IFN at 100 IU was immunostimulating and high dose (10 7 IU) were immunosuppressive. These suggests that feedback mechanism for interferon might be important in oral administration of IFN (Beilharz, 2010) .
In influenza virus infection, low dose of intranasal administration of IFN (up to 5000 IU/dose) were found effective in preventing or alleviating symptoms without serious side effects (Arnaoudova, 1976; Imanishi et al., 1980; Isomura et al., 1982) . Interestingly, subsequent studies of higher doses of IFN (1000~10,000 times more per day) showed no efficacy against influenza viruses (Hayden et al., 1983; Merigan et al., 1973; Phillpotts et al., 1984; Saito et al., 1985; Treanor et al., 1987) , suggesting that the dose of IFN is an important consideration in assessing antiviral effectiveness. In animals, recent studies showed that IFN orally or intranasally delivered to mice (Beilharz et al., 2007; Grimm et al., 2007; Tumpey et al., 2007) , guinea pig (Van Hoeven et al., 2009) or ferrets (Kugel et al., 2009 ) reduced influenza virus replication. Interestingly, oral low-dose IFN (100 IU) were effectively protected mice from a lethal challenge of influenza virus (Beilharz et al., 2007) .
Nanogels are hydrogel particles of less than 1 μm in diameter formed by physically or chemically cross-linked polymer networks. These nanogels can load large amounts of small molecules and/or proteins through spontaneous electrostatic, van der Waals and/or hydrophobic interactions, and show high stability in vitro and in vivo, thus they have huge potential as drugdelivery carriers. It has been shown that nanoencapsulation of peptides and protein colloidal particles protects them against the harsh environment of the gastrointestinal tract due to their covalent nature (Lowe and Temple, 1994) . One of the potential nanogel applications is to deliver functional proteins such as IFN which would be easily degraded in biological solution. Nanogels based on chemically cross-linked networks with PEG and PEI were previously synthesized and demonstrated that they are a good tool to deliver small molecules such as antisense oligonucleotides (Vinogradov et al., 1999) . Despite the beneficial properties of PEG/PEI Ng, it has been associated with cell cytotoxicity in vitro depending on the ratio of PEG/PEI (Ganta et al., 2008) . To overcome this, we acetylated PEG/PEI Ng (AcNg) to block the reactive groups In our study, the incubation of the AcNg in various cells did not show cytotoxicity up to 10 mg/ml (compared to non-acetylated Ng which is toxic at 0.6 mg/ml). The round AgNg particles in the presence or absence of IFN (up to ~ 200 nM diameter) were stable (observed by AFM) for 14 days in PBS solution stored at room temperature (data not shown). Importantly, AcNg significantly increased the stability of IFN, and anti-norovirus (MNV-1 and NV-replicon harboring cells) and HCV activity of IFN in cell culture system were significantly enhanced, compared to IFN alone. In summary, these results suggest that IFN could be used as a therapeutic agent against human norovirus, and AcNg could be a potential drug carrier of IFN by oral route.
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